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Background: For the successful therapeutic use of inhibitors of the vascular endothelial growth factor receptor
(VEGFR) pathway detailed knowledge of the mechanisms leading to tumor progression is indispensable. The main
goal of this study was to determine the relevance of the VEGFR-2 activating pathway for colon carcinoma (CC)
metastasis. The initial event is ligand-induced receptor activation through tyrosine autophosphorylation.
Methods: VEGFR-2, its ligands VEGF-C and VEGF-D and the phosphorylated (activated) receptor forms
pVEGFR-2Tyr1175 and pVEGFR-2Tyr1214 were investigated immunohistochemically in different tumor compartments
(intratumoral (zone 1) - invasive front (zone 2) – extratumoral soft tissue (zone 3)) and various cell types (tumor
cells, inflammatory cells, macro- and microvasculature) in 84 non-metastatic, lymphogenous-metastatic and
haematogenous-metastatic CC.
Results: VEGF-D produced by tumor cells has an autocrine affinity for its receptor VEGFR-2. In tumor budding regions
VEGF-D-induced receptor activation by autophosphorylation at Tyr1214 seems to be a possible initial event of the
VEGFR-2-mediated signaling pathway, but without effect on metastatic behaviour. In inflammatory cells of almost all
CC VEGFR-2 phosphorylation at Tyr 1175 and Tyr 1214 was detectable without accompanying receptor expression,
suggesting receptor activation without cell surface expression. Peritumoral inflammatory cells also expressed
paracrine acting VEGF-C. The autocrine VEGF-D/VEGFR-2 signaling axis and receptor autophosphorylation at Tyr1214
appear to be main events for capillaries in all three tumor zones and for small vessels in zone 1 and 2. Independent
of the metastatic status a large number of cases with capillary immunopositivity in the angiogenically active invasive
front was documented, especially for VEGF-D, VEGFR-2 and pVEGFR-2Tyr1214. VEGFR-2 positive extratumoral capillaries
were significantly more common in distant metastatic CC. In all tumor compartments the investigated biomolecules
were also detected in different frequencies in the macrovasculature, which is responsible for sufficient tumor
vascularization. In addition, vascular paracrine-acting VEGF-C production was widely detected, but without zone
and vessel-type dependence.
Conclusions: The VEGFR-2 activating pathway is closely involved in tumor cell-associated, vessel-mediated and
immuno-inflammatory processes in colon carcinoma and appears to contribute to tumor survival and growth as
well as maintenance of the infiltrative phenotype rather than to promote metastasis.
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More than ten years ago targeted therapy was heralded
as the beginning of a new era in anti-cancer therapy.
The goal of targeted therapy is to interfere with specific
molecules in the tumor to block its growth and spread
[1]. Angiogenesis plays a central role in the processes of
tumor proliferation and metastasis [2]. In angiogenic sig-
naling, vascular endothelial growth factor A (VEGF-A,
also referred to as VEGF) is the most potent angiogenic
factor and its receptor, VEGFR-2, is the predominant
mediator. Thus it is not surprising, that right from the
beginning especially VEGF and VEGFR-2 have been the
main targets for antiangiogenic therapy [3]. However,
the efficacy of antiangiogenic agents appears to be lim-
ited to a subset of the patient cohort. A challenge at the
present time is the establishment of criteria for selecting
the patient group that would benefit from such targeted
therapy. This presumes, however, detailed knowledge of
the specific expression patterns of the target molecules
and their interactive partners within the tumor tissue,
e.g. the presence of the biomolecule, cell-type-affinity,
tumor compartment distribution and activity status. Po-
tential intratumoral and intertumoral differences in the
expression of these factors in various stages of tumor
progression can be better assessed in situ. Indeed, in
histological specimens a sophisticated examination of
the behavior pattern of tumor cells themselves and com-
ponents of the tumor microenvironment in the different
tumor zones is possible and crucial, because firstly,
tumor tissue is highly heterogeneous, and secondly,
angiogenesis, tumor progression and metastasis are de-
cisively regulated by tumor-host interactions. Finally, func-
tional compartmentalization and topological organization
are essential for tumor survival and progression [4–6].
The present study focuses on the expression profiles
of members of the VEGFR-2 – activating pathway in
colon cancer (CC) tumor tissue. Previously, in an immu-
nohistochemical analysis of the VEGFR-1 – activating
pathway in CC, we have shown that VEGF is abundantly
expressed by tumor cells as well as micro- and macro-
vasculature, but without significant correlation with lym-
phogenous or haematogenous metastasis [7]. After its
binding to VEGF, VEGFR-2 dimerizes and undergoes
autophosphorylation of tyrosine residues within its cyto-
plasmic domain, thus initiating the downstream signal-
ing cascades [8]. Takahashi et al. identified Tyr1175 and
Tyr1214 as major autophosphorylation sites in VEGFR-2,
which are located in the C-terminal domain [9]. Tyr1175
is essential for proliferation and migration of endothelial
cells, development of endothelial cells from progenitor
cells, vascular secretion of von Willebrand factor and the
process of vasculogenesis [8]. The Tyr1214 residue is re-
quired to trigger VEGF-induced actin remodelling and
endothelial migration [10]. Data on the phosphorylated(activated) form of VEGFR-2 in tumor tissue and its rele-
vance for tumor progression are very sparse until now. In
addition to VEGF, VEGFR-2 binds proteolytically proc-
essed VEGF-C and VEGF-D [11]. VEGF-C stimulates
receptor dimerization, leading to the formation of
VEGFR-2/VEGFR-3 heterodimers and VEGFR-3/VEGFR-3
homodimers, which are implicated in angiogenesis and
lymphangiogenesis, respectively [12]. Moreover, VEGF-D
activates both receptors, VEGFR-2 and VEGFR-3, and
drives angiogenesis and lymphangiogenesis [13]. In animal
models of cancer, expression of VEGF-C and VEGF-D
consistently promotes growth of blood vessels and lym-
phatics in and around tumors, thus facilitating tumor
growth and enhancing lymph node and distant organ
metastasis. However, the clinical significance of the
VEGF-C and VEGF-D/VEGFRs axes for tumor progres-
sion is unclear. With respect to the involvement of
VEGF-C and VEGF-D in colorectal cancer metastasis
there are conflicting reports [14].
In order to determine the relevance of the VEGFR-2
activating pathway for CC metastasis we investigated the
protein expression profiles of the total and phosphory-
lated forms (Tyr1175 and Tyr1214) of this receptor and
its ligands VEGF-C and VEGF-D in tumor cells as well
as the main components of the tumor microenviron-
ment, namely tumor-associated vasculature and inflam-
matory response in non-metastatic, lymphogenous- and
haematogenous-metastatic sporadic CC. Taking tumor
heterogeneity into consideration, the tumor tissue was
subdivided in three separately investigated, strategically
important compartments, in particular, tumor center
(zone 1), invasive margin (zone 2) and tumor-free sur-
rounding soft tissue (zone 3).
Material and methods
Ethics statement
Ethical approval was granted by the Clinical Research
Ethics Commitee of the federal state of Rhineland-
Palatinate (Mainz, Germany). Written informed consent
was obtained from all patients.
Tissue samples
The CC tissue samples used in this study derived from
84 patients with an average age of 65.2 (range 52–83)
undergoing elective surgery for sporadic CC at the
University of Mainz during the years 1998–2003. All
tumors were staged following the guidelines of the
TNM Classification of Malignant Tumors. With re-
spect to the T status all tumors investigated were T3
(infiltration of subserosa) and moderately differenti-
ated. According to metastatic status 36 of them were
non-metastatic (N0/M0), 24 lymphogenous-metastatic
(N+) and 24 haematogenous-metastatic (M+) CC at
the time of diagnosis.
Table 1 Percentage distribution of the VEGFR-2 ligands VEGF-C
and VEGF-D in tumor cells of CC tissue
Score N0/M0 N+ M+ CC
% % % %
Tumor center
0 37 33 34 35
VEGF-C 1 34 42 57 65
2 29 25 9
0 39 50 54 48
VEGF-D 1 50 50 33 52
2 11 0 13
Tumor budding
0 35 35 16 29
VEGF-C 1 35 40 74 71
2 30 25 10
0 33 50 52 45
VEGF-D 1 63 50 39 55
2 4 0 9
The intensity of the tumoral staining was scored on a semiquantitative scale from
0 to 2 for the investigated biomolecule (0: no staining, 1: weak staining, 2: strong
staining). For the statistical analysis using Fisher’s exact test the examined cases
were separated into two groups, characterized by a negative/positive expression
for VEGF-C and VEGF-D. The line in the staining intensity column indicates this
dichotomization for each biomolecule. There were no significant differences
between the groups
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All immunohistochemical reactions were conducted on
formalin-fixed and paraffin-embedded samples.
VEGF-C, VEGF-D VEGFR-2, pVEGFR-2Tyr1175 and
pVEGFR-2Tyr1214: After deparaffination endogenous per-
oxidase activity was blocked with hydrogen peroxide.
Heat-induced epitope retrieval was performed in citrate
buffer pH 6,0 for 8 min. using a pressure cooker. The
detection kits ZytoChem Plus HRP Kit, anti-Rabbit
and ZytoChem Plus (HRP) Polymer Kit, anti-Mouse
(Zytomed Systems, Berlin, Germany) were utilized fol-
lowing the manufacturer’s instructions. The primary
antibodies were applied for 45 min. at room temperature
and diluted as follows: rabbit polyclonal anti-VEGF-C
(Abcam, Cambridge, UK) 1:800, rabbit polyclonal
anti-VEGF-D (Abcam) 1:200, rabbit monoclonal anti-
VEGFR-2 (SP123, Abcam) 1:1000, rabbit polyclonal
anti-phosphoVEGFR-2 (pY1175, Abcam), 1:100 and rabbit
polyclonal Anti-phosphoVEGFR-2 (pY1214, Abcam) 1:100.
Staining was completed with Novolink Max DAB
(Polymer) Kit (Leica Biosystems, Wetzlar, Germany).
Sections were counterstained with Mayer’s hematoxylin
(Thermo Fisher Scientific, Fremont, USA). To prove the
specificity of the immunoreactions, CC samples were
stained solely with the secondary antibody, omitting the
primary antibody, and served as negative control.
Immunostaining reactions of each sample were evalu-
ated independently by two authors (CJ and NS) without
knowledge of the metastatic status. The endothelial and
inflammatory cell staining was judged as either negative
or positive. The intensity of the tumoral staining was
scored on a semiquantitative scale from 0 to 2 (0: no
staining, 1: weak staining, 2: strong staining). In most
cases the staining was homogeneous. In those cases
where heterogeneous staining was observed, that level of
staining intensity which was visible in more than 50 % of
the cells was chosen for the classification into a defined
group. Tumor budding was defined as single tumor cells
and oligocellular tumor cell clusters (≤5 cells) along the
tumor invasion front. It was delineated as low (< 1/3 of
invasion front) and high (>1/3 of invasion front).
Statistical analysis
Statistical significance was assessed using Fisher’s exact
test. p < 0.05 was considered to be statistically significant.
The correlations between expression of VEGFR-2 and its
ligands as well as pVEGFR-2 were assessed with the
Spearman’s rank test.
Results
Tumor cell- associated VEGFR-2 activation in CC tissue
VEGF-C and VEGF-D were expressed in the cytoplasm
of tumor cells by 65 % and 52 % of the CC, respectively
(Table 1). In tumor budding regions, which reflect thespreading capacity of tumor cells, the percentage distri-
bution of cases with positive VEGFR-2 ligand immuno-
reactivity was similar to the tumor center, namely 71 %
for VEGF-C and 55 % for VEGF-D (Table 1). Both li-
gands were detected with uniform staining intensity
and distribution within the three compared tumor
fractions. There were no significant associations be-
tween metastasis-free and metastatic carcinomas. Ligand/
VEGFR-2 co-expression profiles revealed a nearly uniform
distribution for VEGF-D/VEGFR-2 and an accentuated co-
reactivity in the tumor budding regions for VEGF-C/
VEGFR-2 in the respective metastatic group (Table 2).
However, there were no significant differences concerning
the metastatic state. Correlation analysis displayed a
VEGF-D/VEGFR-2 ligand-receptor affinity in tumor cells
located in the tumor center and in tumor budding regions
(r = 0.425, p = 0.0001 in tumor center and r = 0.421
and p = 0.0002 in tumor budding; Table 3).
In the tumor center and tumor budding regions 54
and 55 % of the CC, respectively, showed a positive cyto-
plasmic VEGFR-2 immunoreaction in tumor cells
without significant differences among the comparative
groups (Table 4). Positive tumoral staining for pVEGFR-
2Tyr1175 and pVEGFR-2Tyr11214 was observed in 64 and
80 % in the tumor core and 67 and 89 % in tumor
budding regions, respectively, but without significant
Table 2 Numerical and percentage distribution of ligand/VEGFR-2
and VEGFR-2/pVEGFR-2 co-expression in the tumor cells
N0/M0 N+ M+
n (%) n (%) n (%)
Tumor center
VEGF-C+/VEGFR-2+ 22/14 (64) 16/9 (56) 14/7 (50)
VEGF-D+/VEGFR-2+ 22/16 (73) 12/10 (83) 11/7 (64)
VEGFR-2+/pVEGFR-2Tyr1175+ 19/14 (74) 13/11 (85) 12/5 (42)
VEGFR-2+/pVEGFR-2Tyr1214+ 19/17 (89) 13/10 (77) 13/11 (85)
Tumor budding
VEGF-C+/VEGFR-2+ 16/12 (75) 10/7 (70) 10/8 (80)
VEGF-D+/ VEGFR-2+ 16/13 (81) 10/8 (80) 13/8 (62)
VEGFR-2+/pVEGFR-2Tyr1175+ 16/11 (69) 10/8 (80) 12/7 (58)
VEGFR-2+/pVEGFR-2Tyr1214+ 16/16 (100) 10/9 (90) 13/13 (100)
n: total number of ligand positive cases/total number of ligand positive cases with
concomitant VEGFR-2 positivity or total number of VEGFR-2 positive cases/total
number of VEGFR-2 positive cases with concomitant pVEGFR-2 positivity. There
were no significant differences between the groups
Table 4 Percentage distribution and statistical significance of
VEGFR-2 and pVEGFR-2 in tumor cells of CC tissue
Score N0/M0 N+ M+ CC
% % % %
Tumor center
VEGFR-2 0 47 46 46 46
1 39 46 50 54
2 14 8 4
Cytoplasmatic VEGFR-2Tyr1175 0 36 29 43 36
1 14 17 14 64
2 50 54 43
Nuclear VEGFR-2Tyr1175 - 6 4 4 5
+ 94 96 96 95
Cytoplasmatic VEGFR-2Tyr1214 0 26 26 8 20
1 31 26 29 80
2 43 48 63
Nuclear VEGFR-2Tyr1214 - 31 26 50 36
+ 69 74 50 64
Tumor budding
VEGFR-2 0 41 50 43 45
1 48 10 43 55
2 11 40 14
Cytoplasmatic VEGFR-2Tyr1175 0 33 30 36 33
1 15 5 14 67
2 52 65 50
Nuclear VEGFR-2Tyr1175 - 4 5 0 3
+ 96 95 100 97
Cytoplasmatic VEGFR-2Tyr1214 0 11 21 0 11
1 22 26 17 89
2 67 53 83
Nuclear VEGFR-2Tyr1214 - 36 21 61 38
+ 67 79 39 62
The intensity of the tumoral staining was scored on a semiquantitative scale from
0 to 2 for the investigated biomolecule (0: no staining, 1: weak staining, 2: strong
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expression in tumor cells had a detectable submembra-
nously accentuated cytoplasmic, and, additionally, nu-
clear staining in virtually all positive CC (Fig. 1a and b).
pVEGFR-2Tyr1214 was seen consistently in tumor cells of
most CC, but with differing cytoplasmic immunostaining
intensity (Table 4). In addition to a submembranously
accentuated cytoplasmic staining a nuclear immuno-
reactivity was seen in 64 % of the cases (Table 4 and
Fig. 1c and d). Neither the cytoplasmic nor the nuclear
expression in tumor cells was statistically significant with
respect to metastasis. However, significant correlations
were found between VEGFR-2 and pVEGFR-2Tyr1214 ex-
pression in tumor budding regions (r = 0.286, p = 0.017;
Table 5). Since a concomitant VEGFR-2/pVEGFR-2
immunopositivity can be interpreted as a potentially
ligand-dependent tyrosine autophosphorylation, co-
expression profiles were analyzed as well. VEGFR-2Tyr1175Table 3 Numerical distribution and statistical significance of
ligand/VEGFR-2 correlations in tumor cells of CC tissue
VEGFR-2 VEGF-C p-value VEGF-D p-value
+ - (r) + - (r)
Tumor center
+ 30 22 NS 33 12 0.0001
- 11 16 12 27 (0.425)
Tumor budding
+ 27 9 NS 29 10 0.0002
- 20 10 10 21 (0.421)
Positive tumoral expression of VEGFR-2 is positively correlated with positive tumoral
VEGF-D expression in tumor center and tumor budding regions. r = Spearman rank
correlation coefficient. p < 0.05 was taken as statistically significant. NS, not significant
staining). For the statistical analysis using Fisher’s exact test the examined cases
were separated into two groups characterized by a negative/positive expression
for VEGFR-2, VEGFR-2Tyr1175 and VEGFR-2Tyr1214. The line in the staining intensity
column indicates this dichotomization for each biomolecule. There were no
significant differences between the groupsco-expression was observed most frequently in N+ CC and
most rarely in M+ CC (Table 2), although significant differ-
ences were not established. Interestingly, almost all tu-
moral VEGFR-2 positive cases exhibited a concomitant
pVEGFR-2Tyr1214 expression in tumor budding regions.
Inflammatory cell-associated VEGFR-2 activation in CC tissue
VEGF-C was markedly expressed in inflammatory cells
in 80–94 % of the cases, independent of the tumor zone
(Table 6). VEGF-D expression was sporadic and occurred
Fig. 1 Immunohistochemical staining of pVEGFR-2 in tumor cells and inflammatory cells of CC tissue. a,b Characteristic pVEGFR-2Tyr1175 expression in tumor
cells with submembranous and nuclear immunostaining in the tumor center (a, x 200) and tumor budding regions (b, x 200). c,d Characteristic pVEGFR-
2Tyr1214 expression in tumor cells with submembranous and nuclear immunostaining in the tumor center (c, x 200) and tumor budding regions (d, x
200). e Characteristic VEGFR-2Ty1175 expression in inflammatory cells (x 200). f Characteristic VEGFR-2Ty1214 expression in inflammatory cells (x 200)
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in the tumor center and in 14 and 27 %, respectively, along
the invasive front. None of the M+ CC showed VEGF-D
immunopositivity. Only few non-metastatic CC in zone 1and 2 and merely two N+ cases in zone 2 displayed a
tumor-associated VEGFR-2 positive inflammatory reaction.
In contrast, independent of the metastatic status and
tumor compartment both phosphorylated VEGFR-2 forms
Table 5 Numerical distribution and statistical significance of
VEGFR-2/pVEGFR-2 correlations in tumor cells of CC tissue
VEGFR-2 pVEGFR-2Tyr1175 p-value pVEGFR-2Tyr1214 p-value
+ − (r) + − (r)
Tumor center
+ 30 14 NS 38 7 NS
- 23 16 27 10
Tumor budding
+ 26 12 NS 38 1 0.017
- 20 11 24 6 (0.286)
Positive tumoral expression of VEGFR-2 is positively correlated with positive tumoral
VEGFR-2Tyr1214 expression in tumor budding regions. r = Spearman rank correlation
coefficient. p < 0.05 was taken as statistically significant. NS, not significant
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omas (Table 6 and Fig. 1e and f).Vasculature-associated VEGFR-2 activation in CC tissue
The vascular expression profiles of the VEGFR-2 activat-
ing pathway were investigated separately in three vessel
types (large vessels, small vessels and capillaries) within
the three zones.
In about half of the investigated carcinomas there was a
positive endothelial VEGF-C expression in capillaries, with
a slight increase in the number of positive cases from the
tumor center towards the invasive front and surrounding
extratumoral tissue (Fig. 2). Particularly noteworthy is the
large number of cases with VEGF-C-positive macrovascu-
lar vessels in all tumor compartments, especially large ves-
sels in the tumor core of metastasizing carcinomas.
However, no significant differences could be established
with respect to the metastatic status.
Independent of the tumor stage, about 40 % of the car-
cinomas had a positive capillary and small vessel-related
VEGF-D immunoreactivity and 40–60 % had a large
vessel-related VEGF-D immunopositivity in the tumor
center (Fig. 2). A marked increase of cases with VEGF-D
positive capillaries and especially macrovascular vessels
from zone 1 to zone 2 and zone 3 was observed. Interest-
ingly, expression of VEGF-D in the macrovasculature was
mainly located in the smooth muscle cells of the mediaTable 6 Percentage distribution of the VEGF-C, VEGF-D, VEGFR-2
and pVEGFR-2 in inflammatory cells of CC tissue
N0/M0 (%) N+ (%) M+ (%)
zone1 zone2 zone1 zone2 zone1 zone2
VEGF-C 88 80 94 86 88 90
VEGF-D 6 14 5 27 0 0
VEGFR-2 12 22 0 9 0 0
VEGFR-2Tyr1175 94 97 94 100 90 100
pVEGFR-2Tyr1214 90 100 94 100 95 100
There were no significant differences between the groupslayer and occasionally in endothelial cells (Fig. 3a). In
the capillaries VEGF-D was expressed by endothelial cells
and pericytes (Fig. 3b). Immature blood vessels with dis-
continuously hypoplastic muscle wall layers were also
stained (Fig. 3c,d).
A zonally subdivided endothelial VEGFR-2 expression
in 58, 90 and 75 % of the cases for capillaries and 56, 86
and 60 % for small vessels was observed with a remarkably
uniform distribution among the investigated groups
(Fig. 4). A pronounced increase of cases with VEGFR-2
positivity in both vascular types was documented from
zone 1 to zone 2. In the invasive front 90 % of the vessels
showed a positive reaction. In zone 3 there were signifi-
cantly more cases with VEGFR-2 positive capillaries in the
distant-metastasic situation in comparison to the non-
metastatic stage (p = 0.03). In all groups large vessel-
associated positive VEGFR-2 immunoreactivity was often
present along the invasive front and additionally in the
tumor center in metastatic carcinomas (N+ and M+)
as well as extratumorally in distant-metastatic CC.
Regardless of the metastatic state, the tumor tissue exhib-
ited endothelial expression of pVEGFR-2Tyr1175 in all seg-
ments of the vascular system and was uniform in all zones
in a large number of cases (Figs. 3e,f and 4). Endothelial ex-
pression of pVEGFR-2Tyr1214 was detectable in the macro-
and microvasculature in a large number of cases, with a dif-
ferent zonal distribution pattern (Figs. 3g,h and 4). From
zone 1 to zone 2 a marked increase in cases with positive
capillaries and small vessels was observed in the non-
metastatic and lymphogenously-metastatic CC. In con-
trast, in distant-metastatic cases these vessel types
showed an approximately constant percentage distribu-
tion in all three zones. Large vessel-associated positive
pVEGFR-2Tyr1214 immunoreactivity was consistently
present in all cases and in all tumor compartments.
Ligand/VEGFR-2 co-expression analysis indicated in zone
2 a co-expression of VEGF-C/D and VEGFR-2 in capillaries
in almost all cases and in small vessels in about 90 % of the
cases (Table 7). In 83–100 % of the cases a capillary and in
77–100 % of the cases a small vessel-associated combined
VEGFR-2/pVEGFR-1Tyr1175 expression was demonstrated,
which was zone-dependent. 88 % of the nodal-positive
cases displayed a concomitant VEGFR-2/pVEGFR-2Tyr1214
expression in capillaries and small vessels (Table 7). In the
other groups an endothelial positivity for the VEGFR-2 total
protein was almost always accompanied by a simultaneous
pVEGFR-2Tyr1214 positivity (91-100 %), independent of the
metastatic status, tumor zone and vessel type.
Significant correlations were found between VEGFR-2
and VEGF-D in vascular expression, except for the small
vessels in zone 3 (Table 8). A similar pattern was noted in
the comparison between VEGFR-2 and pVEGFR-2Tyr1214
expression (Table 8). Additionally, a significant association
between VEGFR-2 and pVEGFR-2Tyr1175 in intratumorally
Fig. 2 Graphical presentation of percentage distribution of VEGF-C and VEGF-D, in the vasculature of CC tissue
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data not shown).
As there were only a small number of cases with de-
tectable large vessels, this vessel type was not considered
for statistical evaluation of co-expression and correlation
analyses. Fig. 5 represents a summary of our results in a
schematic form.
Notably, tumoral and vascular correlation analyses
with previously published expression profiles of the other
VEGFR-2 ligand, VEGF-A, which were investigated in the
same tumor specimens as in the present study, did not lead
to any significant results [7]. Additionally, the VEGF-A/
VEGFR-2 co-expression analysis revealed no statistically
significant differences regarding the metastatic stage.
In the present study expression analysis in lymphatic
vessels was not performed. Based on our experience with
colon carcinoma tissue, a detailed and reproducible
examination of biomolecules localized exclusively in
lymphatic vessels is not possible with conventional
immunohistochemistry.
Discussion
The present study centers on three strategically import-
ant compartments of colon carcinoma (CC) tissue
(tumor center - invasive front - adjacent tumor-free soft
tissue) and represents a systematic analysis of the ex-
pression of total and phosphorylated VEGFR-2 and its
ligands VEGF-C and VEGF-D in the vasculature, tumor
cells and inflammatory cells in relation to metastatic
status.
We demonstrated that CC are characterized by com-
mon immunopositivity for VEGF-C in tumor cells as
well as the macro- and microvasculature and peritu-
moral inflammation. Nevertheless, VEGF-C was notfound to be linked to the metastatic status. Thus, it is
hypothesized that VEGF-C is indeed involved in tumor
cell-tumor microenvironment interactions but, consid-
ered alone, without an instrumental role in progressive
tumor behavior. The prominent VEGF-C detection in
the peritumoral macrovasculature suggests a potential
involvement in events ensuring a functional blood sup-
ply for tumor survival. In most cases VEGF-C was posi-
tive in lymphocytic infiltrates around the tumor glands
and in lymphoid follicles at the tumor periphery. These
findings indicate that VEGF-C is a factor which appears
to be continuously expressed by inflammatory cells in
the CC microenvironment so that the inflammatory
response might act as a possible source of VEGF-C
for paracrine interactions. Considering that immuno-
inflammatory reactions play a dual, partly protective,
partly potentiating role in tumor progression further
studies are needed to confirm the biological relevance
of inflammatory cell-associated VEGF-C expression in
colorectal cancer [15].
VEGF-D expression was detected particularly in
micro- and macrovascular vessels at the invasive front
and in the adjacent tumor-free tissue, but showed no as-
sociation with metastasis. Along with other groups we
have also observed a muscularly accentuated and occa-
sionally endothelial VEGF-D expression in the vascula-
ture [16, 17]. It is noteworthy that near the invasive
front preexisting large vessels as well as immature, pos-
sibly arteriogenetic blood vessels, exhibited VEGF-D.
These data indicate that besides its already documented
(lymph) angiogenic properties VEGF-D could play a role
in the recruitment and possibly also in the arteriogenic
process of vessels to maintain a densely branched vascu-
lar network in the immediate vicinity of the tumor. In
Fig. 3 (See legend on next page.)
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Fig. 3 Immunohistochemical staining of the VEGF-D and pVEGFR-1 in the vasculature of CC tissue. a,bCharacteristic vascular VEGF-D expression. VEGF-D-positive
macrovascular vessels with immunoreactivity in smoothmuscle cells of themedia layer and occasionally in endothelial cells (a, x 200) and VEGF-D-positive capillaries
with endothelial immunoreactivity (b, x 400). Altered macrovascular vessels with discontinuous, hypoplastic smooth muscle cell layer (c, Sm-Actin., x
100) and VEGF-D immunopositivity (d, x 100). e,f Characteristic endothelial VEGFR-2Tyr1175 expression in macrovessels (e, x 200) and capillaries (f, x200).
g,h Characteristic endothelial VEGFR-2Tyr1214 expression in macrovessels (g, x 200) and capillaries (h, x 200)
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mote arteriogenesis [18].
In the literature discrepancies exist regarding the clin-
ical significance of VEGF-C and VEGF-D for colorectal
cancer metastasis. In accordance with our observations,
other research groups also did not establish correlations
between tumor cell expression of VEGF-C and lymph
node/distant colorectal cancer metastasis [19–22]. In
contrast, a number of studies reported that VEGF-C
protein expression is significantly related to lymph node
metastasis [23–29]. In other published reports, VEGF-C
expression, which was detected only at the deepest inva-
sive site of the colon tumor tissue, was significantly
correlated with lymphogenous and haematogenous me-
tastasis [30, 31]. While most studies showed a significant
correlation between VEGF-D protein expression and
nodal metastasis, and in one study even liver metastasis
[20, 21, 23, 32, 33], others failed to find any association
with lymph node involvement [34]. In all cited studies
the immunohistochemical analysis was performedFig. 4 Graphical presentation of percentage distribution of VEGFR-2, and pexclusively in carcinoma cells rather than in the tumor-
associated vasculature. Generally, the conflicting findings
in situ concerning the correlation between VEGF-C and
VEGF-D protein expression and metastasic behavior of
colorectal cancer do not permit a clear assessment. The
analysis of both ligands in tumor tissue is complicated
by the fact that these are proteolytically processed pro-
teins. VEGF-C and VEGF-D are produced as prepropep-
tides and are further processed to a biologically fully
active form that effectively binds to VEGFR-2 and −3
[12, 13]. These biomolecules can therefore be detected
in various forms and subunit compositions with different
functions, which should be taken into account in future
investigations [35].
Interestingly, there was a close correlation between
VEGF-D and its receptor VEGFR-2 expression in both
vasculature and cancer cells, suggesting a tumor cell-
associated and vessel-related VEGF-D/VEGFR-2 autocrine
link in CC, but without direct impact on metastatic spread.
This finding is of crucial therapeutic importanceVEGFR-2 in the vasculature of CC tissue
Table 7 Numerical and percentage distribution of ligand/VEGFR-2
and VEGFR-2/pVEGFR-2 co-expression in the vasculature
N0/M0 N+ M+
n (%) n (%) n (%)
VEGF-C+/VEGFR-2+
Capillaries zone 1 20/8 (40) 9/6 (67) 9/6 (67)
zone 2 16/16 (100) 11/11 (100) 11/9 (82)
zone 3 18/11 (61) 13/11 (85) 16/14 (88)
Small vessels zone 1 16/12 (75) 11/6 (55) 15/8 (53)
zone 2 23/21 (91) 16/15 (94) 17/14 (82)
zone 3 17/9 (53) 14/8 (57) 13/7 (54)
VEGF-D+/VEGFR-2+
Capillaries zone 1 11/10 (91) 8/7 (88) 9/8 (89)
zone 2 19/19 (100) 11/11 (100) 15/14 (93)
zone 3 21/15 (71) 14/12 (86) 12/12 (100)
Small vessels zone 1 10/9 (90) 6/4 (67) 8/5 (63)
zone 2 27/24 (89) 17/16 (94) 19/17 (89)
zone 3 26/16 (62) 19/11 (58) 15/10 (67)
VEGFR-2+/VEGFR-2Tyr1175+
Capillaries zone 1 20/17 (85) 14/14 (100) 12/10 (83)
zone 2 34/31 (91) 21/19 (90) 18/15 (83)
zone 3 22/22 (100) 18/17 (94) 19/18 (95)
Small vessels zone 1 13/10 (77) 8/8 (100) 11/9 (82)
zone 2 29/26 (90) 20/18 (90) 16/14 (88)
zone 3 18/16 (89) 12/12 (100) 9/8 (89)
VEGFR-2+/VEGFR-2Tyr1214+
Capillaries zone 1 19/18 (95) 13/10 (77) 14/13 (93)
zone 2 33/32 (97) 21/19 (90) 21/21 (100)
zone 3 21/21 (100) 15/15 (100) 21/21 (100)
Small vessels zone 1 15/14 (93) 8/6 (75) 11/10 (91)
zone 2 27/27 (100) 20/19 (95) 19/19 (100)
zone 3 17/17 (100) 12/11 (92) 12/12 (100)
n: total number of ligand positive cases / total number of ligand positive cases with
concomitant VEGFR-2 positivity or total number of VEGFR-2 positive cases / total
number of VEGFR-2 positive cases with concomitant pVEGFR-2 positivity. There
were no significant differences between the groups
Table 8 Numerical distribution and statistical significance of
VEGF-D/VEGFR-2 and VEGFR-2/pVEGFR-2Tyr1214 correlations in
the vasculature of CC tissue
VEGFR-2 VEGF-D p-value VEGFR-2Tyr1214 p-value
+/− + - (r) + - (r)
Ca zone 1 25 3 0.0001 41 5 0.0001
23 32 (0.454) 18 16 (0.406)
Ca zone 2 44 1 0.014 72 3 0.0001
32 7 (0.267) 3 4 (0.531)
Ca zone 3 39 8 0.025 57 1 0.001
21 14 (0.256) 17 5 (0.356)
SV zone 1 18 6 0.013 40 4 0.0001
17 20 (0.313) 12 14 (0.494)
SV zone 2 57 6 0.034 65 1 0.0001
11 5 (0.236) 6 4 (0.524)
SV zone 3 37 23 NS 40 1 NS
6 7 25 4
Positive vascular expression of VEGFR-2 is positively correlated with positive
vascular VEGF-D expression and positive vascular VEGFR-2Tyr1214 expression in
capillaries and small vessels in zone 1 and 2 and capillaries in zone 3. r = Spearman rank
correlation coefficient. p < 0.05 was taken as statistically significant. NS, not significant.
Ca = capillaries; SV = small vessels
Jayasinghe et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:42 Page 10 of 13because it has been proposed that regarding tumor
angiogenesis VEGF-D is an alternative mediator to
VEGF-A. This might contribute to mechanisms of re-
sistance to bevacizumab, a widely used anti-cancer drug
targeting VEGF-A [36, 37].
In the invasive front in almost all cases capillaries and
small vessels were VEGFR-2 positive. It is known that
the most aggressive part of the tumor with a high cap-
acity for tumor cell dissociation and initiation of angio-
genesis is located in the invasive front [38]. Nowhere
else is the topographical contact between tumor cells
and functionally active microvasculature so close as
at the invasive front. Thus, the dominant presence ofVEGFR-2 in the strategically important tumor-host inter-
face compartment supports a pivotal role for this receptor
in tumor-vasculature interactions and angiogenesis.
Two observations of vascular VEGFR-2 expression in
distant metastatic CC are of importance. In a relatively
large number of carcinomas with distant metastasis
VEGFR-2 positivity was observed consistently in large
vessels in all zones. This could be interpreted as an in-
timate involvement of VEGFR-2 in the vascularization as
well as vessel survival processes, which are especially im-
portant for metastatic CC that are particularly character-
ized by hypoxia-induced, necrosis-rich areas [39]. In the
extratumoral soft tissue VEGFR-2 positive capillaries oc-
curred significantly more frequently in distant metastatic
CC. It is important to stress that the morphologically
“normal appearing” tissue in the tumor vicinity, although
tumor-free, is not a physiological tissue. On the contrary,
it is an extratumoral area which actively participates in
an intricate crosstalk between tumor and neighboring
tissue, influencing tumor behavior by interacting protein
secretion and receptor activation [40].
In a previous immunohistochemical analysis of almost
the same number of colon and rectum carcinomas low
tumoral VEGFR-2 expression was associated with lymph
node metastasis [41]. In the present study, VEGFR-2
protein exclusively expressed in CC cells, had a uniform
staining intensity and distribution in non-metastatic and
metastatic cases. We suggest that this discrepancy high-
lights the distinct nature of these two types of intestinal
cancer.
Fig. 5 Schematic presentation of VEGFR-2 activation in CC tissue and its association with metastasis. VEGF-D produced by tumor cells in the tumor center
and in tumor budding regions has an autocrine affinity for its receptor VEGFR-2. In dissociated tumor cells VEGF-D-mediated receptor activation by
autophosphorylation at Tyr1214 seems to be a potential signaling pathway but without effect on the metastatic potential. Tumor cells produce
paracrine-acting VEGF-C as well. In inflammatory cells of almost all colon carcinomas there is VEGFR-2 phosphorylation at Tyr 1175 and Tyr 1214 in the
tumor center (zone 1) and invasive front (zone 2), without accompanying receptor expression, suggesting receptor activation without cell surface expression.
Inflammatory cells are also a possible source of paracrine-acting VEGF-C. Autocrine VEGF-D/VEGFR-2 signaling axis and receptor autophosphorylation at
Tyr1214 seem to be main events in CC for capillaries in all three tumor zones and for small vessels in zone 1 and 2. Additionally, the VEGFR-2 receptor of
intratumoral microvessels has a close association with its cytoplasmic tyrosine residue Tyr 1175. Independent of the metastatic status an increase of the
number of cases can be demonstrated with capillary immunopositivity especially for VEGF-D, VEGFR-2 and pVEGFR-2Tyr1214 in the angiogenically active
invasive front. Remarkably, these biomolecules were also often detected in small vessels of marginal tumor areas (zone 2) which are responsible for sufficient
tumor vascularization. VEGFR-2 expression in extratumoral capillaries (zone 3) was significantly more common in distant metastatic CC. In addition,
paracrine-acting VEGF-C production was independent of the zone and vessel type
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expression and concomitant expression with VEGFR-2
was demonstrated in all vascular segments in a large num-
ber of the carcinomas, suggesting a widespread receptor
activation in autoregulatory behavior. The close correl-
ation between VEGFR-2 and pVEGFR-2Tyr1214 expression
in capillaries and small vessels reveals the receptor auto-
phosphorylation at Tyr1214 as a main event for vascular
VEGFR-2-mediated signaling in CC. There were more
cases with pVEGFR-2 positivity in endothelial cells than
tumors with endothelial VEGFR-2 expression. This finding
indicates that ligand-independent receptor phosphoryl-
ation is alternatively available for VEGFR-2 activation inCC. Indeed, besides the classical model of VEGFR-2 activa-
tion through receptor dimerization and autophosphoryl-
ation induced by ligands, the option of ligand-independent
phosphorylation through other kinases under cancerous
conditions such as vascular fluid shear stress and oxidative
stress can also occur [42, 43]. Another ligand-independent
VEGFR2 signaling pathway is an endocytic process with in-
ternalization of the receptor and its activation in cytosolic
regions, such as the Golgi compartment [43, 44]. This
intracellular transport in turn results in progressive de-
crease of VEGFR-2 at the cell surface.
Within the tumor cells, cytoplasmic immunoreactivity
accompanied by a simultaneous nuclear expression was
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2Tyr1175 and in 64 % of the carcinomas regarding
pVEGFR-2Tyr1214. Both expression profiles were not as-
sociated with the metastatic status. A translocation of
pVEGFR-2 to the nucleus in neoplastic cells, including
colon carcinoma cells, has already been reported [45, 46].
These data suggest that in addition to its signal transduc-
tion function VEGFR-2 is involved in the transcriptional
processes of gene regulation.
Both phosphorylated receptor forms, but especially
pVEGFR-2Tyr1214, were frequently expressed in tumor
budding regions, where a significant correlation between
the receptor and its phosphorylated form Tyr1214 was
found. These observations indicate that VEGFR-2 activa-
tion by autophosphorylation in dissociated tumor cells
could possibly mediate the maintenance of an infiltrative
phenotype and the enhancement of migration capacity
in colon cancer.
In almost all cases both pVEGFR-2 forms were
expressed in tumor-associated inflammatory cells with-
out immunohistochemical detection of the total protein.
In accordance with our results, Shin et al. reported that
activated T lymphocytes transcribed mRNA for VEGFR-
1 and VEGFR-2, but only VEGFR1 was expressed on the
T cell surface [47]. Further investigations at both mRNA
and protein levels with additional VEGFR-2 antibodies
are necessary to clarify this specific observation. Never-
theless, the widespread detection of pVEGFR-2 in
inflammatory cells suggests a potential role for the
VEGFR-2 activating pathway in the regulation of im-
mune responses in CC.
Conclusion
Our data indicate that the VEGFR-2 activating pathway
with the ligands VEGF-C and VEGF-D and the phos-
phorylated receptor forms pVEGFR-2Tyr1175 and
pVEGFR-2Tyr1214 is closely involved in events affecting
tumor cells themselves as well as components of the
tumor microenvironment related to blood supply, angio-
genesis and inflammatory response in colon carcinoma.
These processes appear to contribute to tumor survival
and growth as well as maintenance of the infiltrative
phenotype rather than to promote metastasis.
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